{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.9","upperLimit":"71.7","value":"48.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as the time interval from the start of idelalisib treatment to death from any cause. OS was analyzed using KM estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Idelalisib 150 mg tablet administered orally twice daily until tumor progression or development of unacceptable toxicity.","id":"OG000","title":"Idelalisib"}],"paramType":"MEDIAN","populationDescription":"Participants in the ITT Analysis Set were analyzed.","reportingStatus":"POSTED","timeFrame":"Start of Treatment to Last Long-Term Follow-Up Visit (up to maximum of 7 years)","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}